within Pharmacolibrary.Drugs.ATC.R;

model R03CC02_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.000225,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.074,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.105,
    k12             = 80.4,
    k21             = 80.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03CC02_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Salbutamol (also known as albuterol) is a short-acting β2 adrenergic receptor agonist used for the rapid relief and prevention of bronchospasm in conditions such as asthma and COPD. It is globally approved and widely utilized in acute symptomatic management as well as prevention of exercise-induced bronchospasm.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Marques, L, &amp; Vale, N (2022). Salbutamol in the Management of Asthma: A Review. <i>International journal of molecular sciences</i> 23(22) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms232214207&quot;>10.3390/ijms232214207</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36430683/&quot;>https://pubmed.ncbi.nlm.nih.gov/36430683</a></p></li><li><p>Vet, NJ, et al., &amp; de Hoog, M (2020). Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. <i>Clinical pharmacokinetics</i> 59(2) 257–264. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00811-y&quot;>10.1007/s40262-019-00811-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31432470/&quot;>https://pubmed.ncbi.nlm.nih.gov/31432470</a></p></li><li><p>Kruizinga, MD, et al., &amp; Zuiker, RGJA (2020). Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. <i>British journal of clinical pharmacology</i> 86(1) 175–181. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14156&quot;>10.1111/bcp.14156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31658494/&quot;>https://pubmed.ncbi.nlm.nih.gov/31658494</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03CC02_1;
